According to a comprehensive report by Future Market Insights (FMI), the global pediatric diabetes therapeutic market is set to experience substantial growth, with estimates projecting a rise from USD 1,633.8 million in 2024 to USD 2,612.4 million by 2034. This represents a robust compound annual growth rate (CAGR) of 4.8% over the next decade.
Insulin remains a cornerstone in the management of pediatric diabetes, with various formulations designed to mimic natural insulin secretion effectively. CGM systems are becoming increasingly popular as they offer real-time blood sugar readings, enabling timely insulin dose adjustments that can help prevent hypoglycemic and hyperglycemic episodes in young patients.
The shift towards personalized medicine is gaining momentum, thanks to advancements in genetic testing and biomarker analysis. This innovative approach allows healthcare providers to tailor treatments based on individual patient characteristics, potentially optimizing treatment outcomes and minimizing adverse effects.
Track the Latest Market Developments: Request a Sample Report!
Furthermore, the integration of digital health technologies into pediatric diabetes management is transforming the landscape. Smartphone apps, wearable devices, and telemedicine are enhancing remote monitoring and education for patients and caregivers alike. These new technologies are not only improving patient engagement and empowerment but also promoting better treatment adherence, leading to improved clinical outcomes and a more positive patient experience.
As the incidence of pediatric diabetes continues to rise—largely attributed to unhealthy dietary habits—there is an increasing demand for innovative solutions to enhance treatment outcomes. The healthcare industry is responding to this need, focusing on advancements in insulin therapy, glucose monitoring, personalized medicine, and digital health technologies.
Key Takeaways from the Market Study:
- By diabetes, the type 1 diabetes segment is set to surge at a CAGR of 4.2% by 2034.
- By route of administration, the parenteral administration segment accounted for a leading share of 48.4% in the market.
- Distribution channels project the institutional sales segment projected to lead the market at a CAGR of 4.2% by 2034.
- The United States is set to rise at 5.4% CAGR by 2034.
- By country, China is projected to surge at 5.3% CAGR during the forecast period.
“Growing popularity of e-tail and e-commerce has led to the potential of online pharmacies as a promising segment for developing the pediatric diabetes therapeutic market. Governments and healthcare organizations worldwide are exploring biosimilars to improve affordability and patient accessibility,” opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI).
Expanding Market Need: Access Our Full Report for In-Depth Analysis and Trends!
Competitive Landscape:
Leading manufacturers are focusing on research and development of novel therapeutic options to broaden their product portfolio and reach a wide audience. Key companies are directed towards partnerships, collaborations, and alliances to enhance their research, development, and commercialization expertise.
For instance,
- In March 2023, Sanofi, headquartered in France, acquired Provention Bio, a United States-based Biopharmaceutical Company.
- In 2023, AstraZeneca, headquartered in the United Kingdom, received marketing authorization for Bydureon BCise in Europe.
Leading Pediatric Diabetes Therapeutic Brands:
- Boehringer Ingelheim International GmbH
- Eli Lilly and Company
- Sanofi
- Vertex Pharmaceuticals Incorporated
- Novo Nordisk A/S
- AstraZeneca
- MannKind Corporation
- Xeris Pharmaceuticals
- Amphastar Pharmaceuticals, Inc.
Key Segments of Market Report:
By Diabetes:
In terms of diabetes, the category is divided into type 1 and type 2.
By Therapy:
The industry is segregated into drug therapy and insulin therapy. Drug therapy is further divided into biguanide and sodium-glucose co-transporter 2 (SGLT2) inhibitors. Insulin therapy is sub-segmented into rapid-acting insulin, short-acting insulin, intermediate-acting insulin, and long-acting insulin.
By Route of Administration:
The industry is segregated into oral administration, nasal administration, and parenteral administration. The parental administration segment is further trifurcated into subcutaneous, intramuscular, and intravenous.
By Distribution Channel:
A few of the important distribution channels include institutional sales, retail sales, and online pharmacy. Further, the institutional sales segment is branched into hospitals, specialty clinics, and others. Along with that, the retail sales segment is divided into retail pharmacies and drug stores.
By Region:
Key countries of North America, Latin America, East Asia, South Asia and Pacific, Western Europe, Eastern Europe, and the Middle East and Africa are covered.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube